Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 5/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 3/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.36 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.36 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26239278 | 0.87 | KCNH2 (0.39) | KCNH2HTR2ACNR2HRH3CACNA1F | |
| SCHEMBL24600583 | 0.85 | KCNH2 (0.46) | KCNH2CACNA1FCHRM2ACHEAGTR1 | |
| SCHEMBL26239268 | 0.82 | KCNH2 (0.54) | KCNH2CNR2BLMSIGMAR1 | |
| SCHEMBL26240154 | 0.82 | KCNH2 (0.57) | KCNH2CACNA1FCHRM2ACHEAGTR1 | |
| SCHEMBL10726453 | 0.74 | LMNA (0.50) | KCNH2CHRM2CYP3A4SIGMAR1 | |
| SCHEMBL26239281 | 0.71 | KCNH2 (0.49) | KCNH2CNR2BLMSIGMAR1 | |
| SCHEMBL26240216 | 0.70 | KCNH2 (0.52) | KCNH2CACNA1FCHRM2ACHEAGTR1 | |
| SCHEMBL6575856 | 0.69 | KCNH2 (0.56) | KCNH2CYP3A4CYP1A2CYP2D6BLM | |
| SCHEMBL9629107 | 0.68 | KCNH2 (0.54) | KCNH2HRH3CACNA1FCHRM2ACHE | |
| SCHEMBL6574247 | 0.68 | SIGMAR1 (0.42) | KCNH2HRH3CACNA1FCHRM2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025846-A1 | ULTRA SHORT ACTING ANTI-ARRHYTHMIC AGENTS | ACAD PHARMACEUTICALS INC (US) | 2024-01-25 | — | — | US | disclosed |
| US-20240025846-A1 | ULTRA SHORT ACTING ANTI-ARRHYTHMIC AGENTS | ACAD PHARMACEUTICALS INC (US) | 2024-01-25 | — | — | US | disclosed |
| US-11731938-B2 | Ultra short acting anti-arrhythmic agents | ACADEMIC PHARMACEUTICALS INC (US) | 2023-08-22 | — | — | US | disclosed |
| US-11731938-B2 | Ultra short acting anti-arrhythmic agents | ACADEMIC PHARMACEUTICALS INC (US) | 2023-08-22 | — | — | US | disclosed |
| US-20220213032-A1 | ULTRA SHORT ACTING ANTI-ARRHYTHMIC AGENTS | ACADEMIC PHARMACEUTICALS INC | 2022-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213032-A1 | ULTRA SHORT ACTING ANTI-ARRHYTHMIC AGENTS | CACNA1G, SCN5A, CACNA1F | KCNH2 51/4885HTR2A 1549/4885CNR2 2194/4885 |
| US-11731938-B2 | Ultra short acting anti-arrhythmic agents | CACNA1G, SCN5A, CACNA1F | KCNH2 51/4885HTR2A 1549/4885CNR2 2194/4885 |
| US-20240025846-A1 | ULTRA SHORT ACTING ANTI-ARRHYTHMIC AGENTS | CACNA1G, SCN5A, CACNA1F | KCNH2 51/4885HTR2A 1549/4885CNR2 2194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.